The Development and Application of "Scar-care" Padding on Management of Hypertrophic Scar

March 27, 2018 updated by: The Hong Kong Polytechnic University

The Effectiveness of a Smart Scar Care Pad and Pressure Therapy Versus Pressure Therapy in Hypertrophic Scar Management: a Pilot Study

This study explores the smart scar care pad's potential therapeutic effect in treatment hypertrophic scar while elucidating the adverse effects if there is any. Half of the participant receives traditional treatment of pressure garment and the other half receives the smart scar care pad together with pressure garment.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

8

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Subjects with Hypertrophic Scar(HS);
  2. the HS had a total Vancouver Scar Scale (VSS) score of 4 or higher and the score of each item equal to or greater than 1;
  3. subjects age between 20 and 70 years, cooperative, and good compliance with treatment.

Exclusion Criteria:

  1. the HS area had an open wound or infection;
  2. the HS had been treated with steroid injections or other intervention (such as traditional Chinese medicine or laser therapy) before the study; or
  3. the patient had a medical condition that might affect wound healing (e.g., diabetes mellitus or another serious medical problem).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SSCP & SPMS

The smart scar care pad (SCCP):

The SCCP is a newly invented insert material that can maximise treatment outcomes via enhanced compression and occlusion. The wearing regime for SCCP is 4 hours a day for the first day, with 2-hour increments added every other day until the total wearing time reached 23 hours. SSCP was cleaned twice a day for hygienic reasons.

The smart pressure monitored suit(SPMS):

The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering.

Insert
Other Names:
  • The Smart Scar Care PAd
Pressure therapy
Other Names:
  • The Smart Pressure Monitored Suit
Active Comparator: SPMS

The smart pressure monitored suit(SPMS):

The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering.

Pressure therapy
Other Names:
  • The Smart Pressure Monitored Suit

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of Scar Pliability measured by the DermaLab Combo
Time Frame: baseline and 6 weeks
Scar pliability is represented by the Young's modulus measured by the elasticity measurement of the DermaLab Combo
baseline and 6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of Scar Thickness measured by the diagnostic ultrasound system
Time Frame: baseline and 6 weeks
Scar thickness is measured by the diagnostic ultrasound system
baseline and 6 weeks
Change of Scar Pigmentation measured by the DermaLab Combo
Time Frame: baseline and 6 weeks
Scar pigmentation is represented by the melanin score generated by the color probe of the DermaLab Combo. The range of the score is 0-100, where a higher score indicates a higher melanin content.
baseline and 6 weeks
Change of Scar Vascularity measured by the DermaLab Combo
Time Frame: baseline and 6 weeks
Scar vascularity is represented by the erythema score measured by the color probe of the DermaLab Combo. The range of the score is 0-100, where a higher score indicates a more erythematic situation.
baseline and 6 weeks
Occurrence of blistering
Time Frame: up to 6 weeks
Occurence of blistering is observed and reported by research staff
up to 6 weeks
Occurrence of skin breakdown
Time Frame: up to 6 weeks
Occurence of skin breakdown is observed and reported by research staff
up to 6 weeks
Occurrence of rash
Time Frame: up to 6 weeks
Occurence of rash is observed and reported by research staff
up to 6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2015

Primary Completion (Actual)

November 1, 2016

Study Completion (Actual)

November 1, 2016

Study Registration Dates

First Submitted

March 13, 2018

First Submitted That Met QC Criteria

March 13, 2018

First Posted (Actual)

March 19, 2018

Study Record Updates

Last Update Posted (Actual)

March 29, 2018

Last Update Submitted That Met QC Criteria

March 27, 2018

Last Verified

March 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • HSEARS20140618002-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rehabilitation

Clinical Trials on SSCP

3
Subscribe